Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q6PIL6

UPID:
KCIP4_HUMAN

ALTERNATIVE NAMES:
A-type potassium channel modulatory protein 4; Calsenilin-like protein; Potassium channel-interacting protein 4

ALTERNATIVE UPACC:
Q6PIL6; Q3YAB8; Q3YAB9; Q3YAC0; Q3YAC1; Q3YAC2; Q4W5G8; Q8NEU0; Q9BWT2; Q9H294; Q9H2A4

BACKGROUND:
The Kv channel-interacting protein 4, with alternative names such as Calsenilin-like protein and Potassium channel-interacting protein 4, is integral in regulating A-type potassium channels. It specifically influences KCND2 and KCND3/Kv4.3 currents, affecting channel density and inactivation kinetics in a calcium-dependent manner. Isoform-specific actions, such as isoform 4's negative regulation of KCND3 membrane expression, underscore the protein's complex regulatory roles.

THERAPEUTIC SIGNIFICANCE:
The exploration of Kv channel-interacting protein 4's functions presents a promising avenue for drug discovery. Given its pivotal role in potassium channel regulation, targeting this protein could yield novel therapeutic approaches for managing diseases linked to potassium channel anomalies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.